Evidence map›Paper›PMID 35149914›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2022

Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival.

Arnaud Jannin, Livia Lamartina, Coralie Moutarde, Mehdi Djennaoui, George Lion, Benjamin Chevalier, Marie Christine Vantyghem, Frédéric Deschamps, Julien Hadoux, Eric Baudin and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Arnaud JanninDepartment of Endocrinology and Metabolism, University Hospital of Lille, Lille, France. arnaud.jannin.aj@gmail.com.ORCID http://orcid.org/0000-0002-6031-4816
Livia LamartinaGustave Roussy, Service d'oncologie Endocrinienne, Département d'Imagerie, University Paris Saclay, Cedex, Villejuif, France.
Coralie MoutardeDepartment of Endocrinology and Metabolism, Armentières Hospital, Armentières, France.
Mehdi DjennaouiDepartment of Public Health, Valenciennes Hospital, Valenciennes, France.
George LionDepartment of Nuclear Medicine, University Hospital of Lille and Lille University, Lille, France.
Benjamin ChevalierDepartment of Endocrinology and Metabolism, University Hospital of Lille, Lille, France.
Marie Christine VantyghemDepartment of Endocrinology and Metabolism, University Hospital of Lille, Lille, France.
Frédéric DeschampsGustave Roussy, Department of Interventional Radiology, University Paris Saclay, Villejuif Cedex, France.
Julien HadouxGustave Roussy, Service d'oncologie Endocrinienne, Département d'Imagerie, University Paris Saclay, Cedex, Villejuif, France.
Eric BaudinGustave Roussy, Service d'oncologie Endocrinienne, Département d'Imagerie, University Paris Saclay, Cedex, Villejuif, France.
Martin SchlumbergerGustave Roussy, Service d'oncologie Endocrinienne, Département d'Imagerie, University Paris Saclay, Cedex, Villejuif, France.
Sophie LeboulleuxGustave Roussy, Service d'oncologie Endocrinienne, Département d'Imagerie, University Paris Saclay, Cedex, Villejuif, France.
Christine Do CaoDepartment of Endocrinology and Metabolism, University Hospital of Lille, Lille, France.
Université Paris-Saclay · FRUniversité de Lille · FRCentre Hospitalier de Valenciennes · FRCentre Hospitalier Universitaire de Lille · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBone metastases (BM) from differentiated thyroid carcinoma (DTC) impact negatively the quality of life and the life expectancy of patients. The aim of the study was (a) to evaluate the overall survival (OS) and prognostic factors of OS and (b) to assess predictive factors of complete BM response (C-BM-R) using radioiodine treatment (RAI) either alone or in association with focal treatment modalities.

methodsA total of 178 consecutive DTC patients harbouring BM, treated between 1989 and 2015, were enrolled in this retrospective study conducted in two tertiary referral centers. OS analysis was performed for the whole cohort, and only the 145 considered non-RAI refractory patients at BM diagnosis were evaluated for C-BM-R following RAI.

resultsThe median OS from BM diagnosis was 57 months (IQR: 24-93). In multivariate analysis, OS was significantly reduced in the case of T4 stage,

conclusionsIn nearly one-third of DTC patients with RAI avid BM, RAI alone or in combination with BM focal treatment can induce C-BM-R. The presence of

Indexed as

AdenocarcinomaBone NeoplasmsThyroid NeoplasmsFluorodeoxyglucose F18HumansIodine RadioisotopesPositron Emission Tomography Computed TomographyQuality of LifeRetrospective StudiesFluorodeoxyglucose F18Iodine RadioisotopesBone metastasesFocal treatmentRadioiodineSkeletal-related eventsThyroid carcinoma

Identifiers

PMID35149914
PMCPMC9165254
OpenAlexW4211153498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.